A 38-year-old patient describes six months of distressing low sexual desire. Her hormones are unremarkable, she is not depressed, her relationship is stable, and she is premenopausal — yet the absence of desire is causing her real distress. She has read about “PT-141” online and asks whether it could help. For many nurse practitioners, this is the moment the science of PT-141 (bremelanotide) becomes clinically relevant rather than academic. Bremelanotide is unusual among sexual-health agents because it acts centrally, on the brain’s melanocortin system, rather than peripherally on blood flow. Understanding that distinction — and knowing exactly where the FDA-approved product (Vyleesi) ends and compounded “PT-141” begins — is essential before an NP discusses it with any patient.
How Bremelanotide Works: The Melanocortin Pathway
Most sexual-health pharmacology that NPs encounter targets the periphery. Phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil increase genital blood flow but do nothing for desire. Bremelanotide works upstream of all of that. It is a synthetic cyclic heptapeptide that, per the FDA Vyleesi prescribing information, nonselectively activates several melanocortin receptor subtypes; at therapeutic dose levels, binding to the MC1R and MC4R subtypes is the most relevant, and activation of melanocortin-4 receptors (MC4R) in the central nervous system is the mechanism associated with its effect on sexual desire.[^fda-vyleesi][^melanocortin-review]
The practical takeaway for prescribers: bremelanotide modulates desire and arousal at the level of the brain, which is why it is studied for hypoactive sexual desire disorder (HSDD) — a disorder of desire — rather than for the mechanical aspects of arousal that PDE5 inhibitors address. This central mechanism also explains its side-effect profile, discussed below, since melanocortin receptors are distributed widely (skin, cardiovascular tissue, the GI tract) and not confined to the CNS.
- Drug class: melanocortin receptor agonist (a peptide therapeutic)
- Site of action: central (CNS), distinct from peripheral vasodilators
- Receptor target: nonselective melanocortin receptor agonist; at therapeutic doses, MC1R and MC4R binding is most relevant, with MC4R activation implicated in sexual response[^fda-vyleesi]
For a foundational overview of how peptides are classified and prescribed, see our primer on peptide therapy.
The FDA-Approved Indication: Vyleesi for HSDD
This is the section where accuracy matters most. Bremelanotide is FDA-approved and marketed as Vyleesi. The approval is narrow and specific: following its initial U.S. approval in 2019, Vyleesi is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty.[^fda-vyleesi]
Each term in that indication is doing work:
- Acquired — the patient previously had a satisfactory level of sexual desire that has since declined; it is not lifelong.
- Generalized — the low desire is not limited to a specific partner, situation, or type of stimulation.
- Premenopausal women — the population studied and approved. The FDA label limits the indication to premenopausal women; Vyleesi has not been evaluated for or approved in postmenopausal women or in men.[^fda-vyleesi]
HSDD itself is a recognized clinical diagnosis with a defined workup, and a desire complaint should never be treated pharmacologically without that workup. For the full diagnostic framework — biopsychosocial assessment, hormone evaluation, and where bremelanotide fits among the treatment options — see our companion piece on hypoactive sexual desire disorder in women in the women’s health cluster.
Compounded “PT-141” is a distinct category. The FDA approval described above covers only the Vyleesi product for the labeled premenopausal-HSDD indication; any use of compounded “PT-141” falls outside that approval and is therefore not FDA-approved.[^fda-vyleesi] When prepared by a legitimate 503A or 503B compounding pharmacy, compounding is a well-established, regulated practice that can expand patient access to therapies that are otherwise unavailable in a suitable form — and it is how many peptide therapies reach patients. The important distinction for NPs is the source: legitimate compounding pharmacies are very different from research-chemical and black-market suppliers, which should never be used for patient care. Uses outside the approved Vyleesi indication remain off-label and carry their own clinical and regulatory considerations.
Dosing and Administration
For the FDA-approved product, the label itself defines the regimen. Per the FDA Vyleesi prescribing information, Vyleesi is supplied as a subcutaneous autoinjector for self-administration into the abdomen or thigh, and the approved dose is 1.75 mg given at least 45 minutes before anticipated sexual activity, with two label limits that are clinically important: no more than one dose within any 24-hour period and no more than eight doses per month.[^fda-vyleesi]
A key counseling point is that bremelanotide is taken on demand, not on a fixed daily schedule — patients may expect a daily pill.
Beyond these labeled parameters, candidate selection, patient counseling, trial-and-reassessment, and the protocol considerations around compounded peptide therapy are exactly the kind of prescriber-level detail covered in the Anti-Aging & Peptide Course rather than reproduced here.
Safety, Adverse Effects, and Contraindications
The melanocortin mechanism predicts much of the safety profile. NPs counseling patients should be comfortable with the following:
| Domain | What to know |
| Most common AE | Nausea — the most commonly reported effect (reported in 40% of treated patients in trials), especially with the first dose, but generally mild and short-lived ; an antiemetic helps the minority who need it.[^fda-vyleesi] |
| Other common AEs | Flushing, injection-site reactions, headache, and vomiting — typically mild .[^fda-vyleesi] |
| Cardiovascular | Transient increases in blood pressure and decreases in heart rate after each dose (peaking around 6 mmHg systolic / 3 mmHg diastolic, with heart rate down up to 5 bpm) that typically resolve within about 12 hours; nonetheless contraindicated in uncontrolled hypertension or known cardiovascular disease. [^fda-vyleesi] |
| Hyperpigmentation | Focal hyperpigmentation (including of the face, gingiva, and breasts) is possible but uncommon (reported in 1% of patients receiving up to 8 doses per month), more likely in patients with darker skin and with daily dosing, and not always fully reversible; melanocortin activity on melanocytes is the mechanism.[^fda-vyleesi] |
| Drug interactions | May slow gastric emptying and reduce absorption of concomitantly administered oral medications; avoid use with orally administered naltrexone-containing products intended to treat alcohol or opioid addiction, because Vyleesi can significantly decrease naltrexone exposure.[^fda-vyleesi] |
These safety data come from the studied, FDA-approved Vyleesi product and its prescribing information.[^fda-vyleesi] Because the FDA approval covers only that product for its labeled use, the safety of compounded “PT-141” preparations, alternate routes, and off-label populations is not characterized by that approval — which is one more reason to work through a legitimate compounding pharmacy and an evidence-based protocol.
Where PT-141 Fits in an NP’s Sexual-Health Toolkit
Bremelanotide is not a first-line, one-size-fits-all answer to low desire — and framing it that way is a clinical and compliance error. It is one option within a structured approach to HSDD that begins with a proper diagnosis, rules out medication-induced and hormonal causes, and incorporates psychological and relational factors. For premenopausal women with acquired, generalized HSDD who are appropriate candidates, it offers a centrally acting, on-demand mechanism that the peripheral agents simply do not provide.
For nurse practitioners building sexual-health and peptide competencies into their practice, the clinically responsible path is to understand the melanocortin pharmacology, the precise boundaries of the FDA-approved indication, and the regulatory landscape around compounded peptides before prescribing. That is exactly the kind of prescriber-level depth the Anti-Aging & Peptide Course is built to provide.
Frequently Asked Questions
What is PT-141 (bremelanotide)?PT-141, known generically as bremelanotide, is a synthetic peptide that acts as a melanocortin receptor agonist. It works centrally in the brain to influence sexual desire, distinguishing it from PDE5 inhibitors that act on genital blood flow. Its FDA-approved form is marketed as Vyleesi.
Is bremelanotide FDA-approved?Yes. Bremelanotide is FDA-approved as Vyleesi for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It is not FDA-approved for men or for postmenopausal women, and compounded “PT-141” used for those populations is off-label.[^fda-vyleesi]
How is Vyleesi (bremelanotide) dosed?Vyleesi is a 1.75 mg subcutaneous injection given by autoinjector at least 45 minutes before anticipated sexual activity. Patients should take no more than one dose in 24 hours and no more than eight doses per month.[^fda-vyleesi]
What are the most common side effects of bremelanotide?Nausea is the most commonly reported side effect, particularly with the first dose, but it is usually mild and short-lived. Other effects, also typically mild, include flushing, injection-site reactions, and headache. Bremelanotide can cause mild, transient blood-pressure increases, and focal skin hyperpigmentation is possible but uncommon, mainly with frequent repeated use.[^fda-vyleesi]
How is PT-141 different from sildenafil (Viagra)?PT-141 acts centrally on the brain’s melanocortin system to affect sexual desire, whereas sildenafil acts peripherally as a PDE5 inhibitor to improve genital blood flow and arousal mechanics. They target different parts of the sexual-response pathway and are studied for different problems.
Conclusion
PT-141 (bremelanotide) is a clinically distinctive, centrally acting melanocortin agonist — FDA-approved as Vyleesi specifically for acquired, generalized HSDD in premenopausal women. For NPs, the value lies in knowing the mechanism, respecting the narrow approved indication, and clearly separating Vyleesi from compounded “PT-141” uses, which are off-label and carry their own safety and regulatory questions. Ready to prescribe peptides with prescriber-level confidence? Explore the Anti-Aging & Peptide Course for the clinical and regulatory depth NPs need.
Sources
U.S. Food and Drug Administration. VYLEESI (bremelanotide injection), for subcutaneous use — Highlights of Prescribing Information. Initial U.S. Approval: 2019 (AMAG Pharmaceuticals). Full prescribing information via DailyMed: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c9607a2-5b57-4a59-b159-cf196deebdd9. FDA Drugs@FDA approval record (NDA 210557): https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210557. Accessed June 26, 2026. (Source of all indication, mechanism, dosing, adverse-reaction, contraindication, and drug-interaction statements in this article.)
Mayer D, Lynch SE. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder. Ann Pharmacother. 2020;54(7):684-690. doi:10.1177/1060028019899152. PubMed: https://pubmed.ncbi.nlm.nih.gov/31893927/. See also Kingsberg SA, Clayton AH, Portman D, et al. neurobiology of bremelanotide for HSDD (CNS Spectrums) and Clayton AH, et al. J Womens Health. Accessed June 26, 2026. (Supporting peer-reviewed references for the melanocortin-pathway / MC4R mechanism of action.)
